Atara Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATRA Nasdaq 2836 www.atarabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atara Biotherapeutics, Inc.

Epstein Barr Virus Research Analysis Report 2025-2035: Market Led by AstrViracta, Atara, AlloVir, and Pierre Fabre as Antiviral and Immune-Modulating Therapy Innovation Accelerates - Nov 18th, 2025 8:14 am
Atara Biotherapeutics: Q3 Earnings Snapshot - Nov 12th, 2025 7:11 am
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Nov 12th, 2025 7:00 am
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates - Nov 10th, 2025 6:45 am
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? - Nov 7th, 2025 4:45 am
Pacira (PCRX) Tops Q3 Earnings Estimates - Nov 6th, 2025 4:10 pm
Adma Biologics (ADMA) Q3 Earnings Match Estimates - Nov 5th, 2025 4:25 pm
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - Nov 3rd, 2025 7:00 am
While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership - Oct 3rd, 2025 4:51 am
Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock? - Sep 25th, 2025 7:28 am
Atara Biotherapeutics Announces Changes to Its Board of Directors - Sep 3rd, 2025 4:00 pm
In cell therapy, cost is a hot issue. The industry might need a cold solution. - Aug 19th, 2025 3:00 am
Atara Biotherapeutics Second Quarter 2025 Earnings: Beats Expectations - Aug 14th, 2025 4:17 am
Atara Biotherapeutics: Q2 Earnings Snapshot - Aug 11th, 2025 3:53 pm
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - Aug 11th, 2025 2:01 pm
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Is About To Turn The Corner - Aug 5th, 2025 5:50 am
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - Jul 24th, 2025 6:57 am
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Jul 24th, 2025 6:00 am
Rocket lays off staff; Abivax capitalizes on immune drug data - Jul 24th, 2025 4:55 am
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - Jul 15th, 2025 6:00 am